Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals
Background To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as ‘levodopa equivalent dose’ (LED). Currently, t...
Uloženo v:
| Vydáno v: | Movement disorders Ročník 38; číslo 7; s. 1236 - 1252 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Hoboken, USA
John Wiley & Sons, Inc
01.07.2023
Wiley Subscription Services, Inc |
| Témata: | |
| ISSN: | 0885-3185, 1531-8257, 1531-8257 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as ‘levodopa equivalent dose’ (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed.
Objectives
To update LED conversion formulae based on a systematic review.
Methods
The MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency.
Results
The systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon.
Conclusions
The LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non‐pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
|---|---|
| AbstractList | Background
To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as ‘levodopa equivalent dose’ (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed.
Objectives
To update LED conversion formulae based on a systematic review.
Methods
The MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency.
Results
The systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon.
Conclusions
The LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non‐pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. BackgroundTo compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as ‘levodopa equivalent dose’ (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed.ObjectivesTo update LED conversion formulae based on a systematic review.MethodsThe MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency.ResultsThe systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon.ConclusionsThe LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non‐pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. Background: To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as ‘levodopa equivalent dose’ (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed. Objectives: To update LED conversion formulae based on a systematic review. Methods: The MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency. Results: The systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon. Conclusions: The LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non-pharmacological interventions in PD. To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as 'levodopa equivalent dose' (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed.BACKGROUNDTo compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as 'levodopa equivalent dose' (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed.To update LED conversion formulae based on a systematic review.OBJECTIVESTo update LED conversion formulae based on a systematic review.The MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency.METHODSThe MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency.The systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon.RESULTSThe systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon.The LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non-pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.CONCLUSIONSThe LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non-pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as 'levodopa equivalent dose' (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed. To update LED conversion formulae based on a systematic review. The MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency. The systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon. The LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non-pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
| Author | Cardoso, Francisco Schade, Sebastian Stocchi, Fabrizio Dafsari, Haidar S. Rodríguez‐Violante, Mayela Deuschl, Guenther Petry‐Schmelzer, Jan Niklas Metta, Vinod Katzenschlager, Regina Fung, Victor S.C. Fasano, Alfonso Kukkle, Prashanth Lingappa Jost, Stefanie T. Bhidayasiri, Roongroj Falup‐Pecurariu, Cristian Espay, Alberto J. Odin, Per Timmermann, Lars Jenner, Peter Martinez‐Martin, Pablo Antonini, Angelo Tan, Eng‐King Borgohain, Rupam Ray Chaudhuri, K. Hattori, Nobutaka Weintraub, Daniel Kaldenbach, Marie‐Ann Trenkwalder, Claudia |
| Author_xml | – sequence: 1 givenname: Stefanie T. orcidid: 0000-0003-0477-2289 surname: Jost fullname: Jost, Stefanie T. organization: Faculty of Medicine and University Hospital Cologne, University of Cologne – sequence: 2 givenname: Marie‐Ann surname: Kaldenbach fullname: Kaldenbach, Marie‐Ann organization: Faculty of Medicine and University Hospital Cologne, University of Cologne – sequence: 3 givenname: Angelo orcidid: 0000-0003-1040-2807 surname: Antonini fullname: Antonini, Angelo organization: University of Padua – sequence: 4 givenname: Pablo orcidid: 0000-0003-0837-5280 surname: Martinez‐Martin fullname: Martinez‐Martin, Pablo organization: Carlos III Institute of Health – sequence: 5 givenname: Lars surname: Timmermann fullname: Timmermann, Lars organization: University Hospital Giessen and Marburg – sequence: 6 givenname: Per surname: Odin fullname: Odin, Per organization: Skåne University Hospital – sequence: 7 givenname: Regina surname: Katzenschlager fullname: Katzenschlager, Regina organization: Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders at Klinik Donaustadt – sequence: 8 givenname: Rupam surname: Borgohain fullname: Borgohain, Rupam organization: Nizam's Institute of Medical Sciences – sequence: 9 givenname: Alfonso orcidid: 0000-0001-5346-0180 surname: Fasano fullname: Fasano, Alfonso organization: Moriggia‐Pelascini Hospital–Gravedona ed Uniti – sequence: 10 givenname: Fabrizio surname: Stocchi fullname: Stocchi, Fabrizio organization: University and Institute for Research and Medical Care IRCCS San Raffaele – sequence: 11 givenname: Nobutaka surname: Hattori fullname: Hattori, Nobutaka organization: Juntendo University Graduate School of Medicine – sequence: 12 givenname: Prashanth Lingappa orcidid: 0000-0002-4610-947X surname: Kukkle fullname: Kukkle, Prashanth Lingappa organization: Parkinson's Disease and Movement Disorders Clinic – sequence: 13 givenname: Mayela orcidid: 0000-0002-6041-9941 surname: Rodríguez‐Violante fullname: Rodríguez‐Violante, Mayela organization: National Institute of Neurology and Neurosurgery – sequence: 14 givenname: Cristian surname: Falup‐Pecurariu fullname: Falup‐Pecurariu, Cristian organization: County Emergency Clinic Hospital – sequence: 15 givenname: Sebastian orcidid: 0000-0002-6316-6804 surname: Schade fullname: Schade, Sebastian organization: University Medical Center Göttingen – sequence: 16 givenname: Jan Niklas orcidid: 0000-0003-0749-3840 surname: Petry‐Schmelzer fullname: Petry‐Schmelzer, Jan Niklas organization: Faculty of Medicine and University Hospital Cologne, University of Cologne – sequence: 17 givenname: Vinod surname: Metta fullname: Metta, Vinod organization: King's College London – sequence: 18 givenname: Daniel orcidid: 0000-0003-0633-7168 surname: Weintraub fullname: Weintraub, Daniel organization: Corporal Michael J. Crescenz Veterans Affairs Medical Center – sequence: 19 givenname: Guenther orcidid: 0000-0002-4176-9196 surname: Deuschl fullname: Deuschl, Guenther organization: University Hospital Schleswig‐Holstein (UKSH), Christian‐Albrechts‐University Kiel – sequence: 20 givenname: Alberto J. orcidid: 0000-0002-3389-136X surname: Espay fullname: Espay, Alberto J. organization: University of Cincinnati – sequence: 21 givenname: Eng‐King surname: Tan fullname: Tan, Eng‐King organization: Duke–NUS Medical School – sequence: 22 givenname: Roongroj orcidid: 0000-0002-6901-2064 surname: Bhidayasiri fullname: Bhidayasiri, Roongroj organization: The Royal Society of Thailand – sequence: 23 givenname: Victor S.C. orcidid: 0000-0003-3085-2282 surname: Fung fullname: Fung, Victor S.C. organization: Westmead Hospital – sequence: 24 givenname: Francisco orcidid: 0000-0003-0808-0116 surname: Cardoso fullname: Cardoso, Francisco organization: Universidade Federal de Minas Gerais – sequence: 25 givenname: Claudia surname: Trenkwalder fullname: Trenkwalder, Claudia organization: University Medical Center Göttingen – sequence: 26 givenname: Peter surname: Jenner fullname: Jenner, Peter organization: King's College London – sequence: 27 givenname: K. surname: Ray Chaudhuri fullname: Ray Chaudhuri, K. organization: South London and Maudsley NHS Foundation Trust and King's College London – sequence: 28 givenname: Haidar S. surname: Dafsari fullname: Dafsari, Haidar S. email: haidar.dafsari@uk-koeln.de organization: Faculty of Medicine and University Hospital Cologne, University of Cologne |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37147135$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc1u1DAUhS1URKeFBS-ALLGALtLasZ043aFOC0iDqGhZsLIc-0a4JHZqJzOat8d0piwqWN3Nd350zxE68MEDQq8pOaWElGeDTadlwyl5hhZUMFrIUtQHaEGkFAWjUhyio5TuCKFU0OoFOmQ15TVlYoF-rGAdbBg1XoYE-PJ-dmvdgzdb7Dy-1vGX8yn4dwkvXQKd4Bx_H62ewOKbbZpg0JMz-BusHWyw9hZfxzCGpPv0Ej3v8oFX-3uMbq8uby8-FauvHz9ffFgVRnBOippD1UgjBTVtBxWvmrq2RGvGOtKQumqBc1o3vGplRTUvpS15yalttbZAO3aM9M42bWCcWzVGN-i4VUE7NYY46V5FyM2j-an6WSVQmeqdyb2DT8oIwmtDiBLAqOJdK5SGzqj8nYYzw7jpWM54v8sYY7ifIU1qcMlA32sPYU6qlJQ0VGanjL59gt6FOfr8gExxRngphMzUmz01twPYv6Ufd8nA2Q4wMaQUoVPGTQ-Vp6hdryhRf5ZXeXn1sHxWnDxRPJr-i927b1wP2_-D6svyZqf4DTjPvMU |
| CitedBy_id | crossref_primary_10_1002_mdc3_70314 crossref_primary_10_1016_j_nbd_2024_106609 crossref_primary_10_1038_s41531_025_00889_1 crossref_primary_10_1177_1877718X251324413 crossref_primary_10_1038_s41531_025_01030_y crossref_primary_10_1002_mdc3_14056 crossref_primary_10_3389_fneur_2025_1657824 crossref_primary_10_1002_brb3_70822 crossref_primary_10_1080_13543784_2023_2263357 crossref_primary_10_1111_nmo_15005 crossref_primary_10_3389_fphar_2025_1529932 crossref_primary_10_3390_ijms25126402 crossref_primary_10_3390_brainsci15050532 crossref_primary_10_1016_j_nbd_2024_106560 crossref_primary_10_3233_JPD_230446 crossref_primary_10_1007_s10072_025_08081_2 crossref_primary_10_3390_jcm13247566 crossref_primary_10_1038_s41586_025_08700_0 crossref_primary_10_1016_j_jns_2023_120831 crossref_primary_10_1038_s41531_024_00701_6 crossref_primary_10_1038_s41598_025_03088_3 crossref_primary_10_1016_j_neurot_2025_e00561 crossref_primary_10_1038_s41598_023_46003_4 crossref_primary_10_1016_j_jns_2024_123283 crossref_primary_10_1038_s41531_024_00808_w crossref_primary_10_1016_j_npep_2025_102534 crossref_primary_10_1177_1877718X251356896 crossref_primary_10_1016_j_bbr_2025_115664 crossref_primary_10_1016_j_parkreldis_2025_108055 crossref_primary_10_1038_s41467_024_48732_0 crossref_primary_10_1002_agm2_70033 crossref_primary_10_1002_mds_29671 crossref_primary_10_1002_mdc3_70334 crossref_primary_10_1097_JS9_0000000000002018 crossref_primary_10_1038_s41591_024_03270_6 crossref_primary_10_3389_fnagi_2023_1258315 crossref_primary_10_1007_s10286_024_01071_y crossref_primary_10_1016_j_neurom_2024_09_473 crossref_primary_10_1177_1877718X241305711 crossref_primary_10_1044_2024_JSLHR_23_00525 crossref_primary_10_4103_aian_aian_676_25 crossref_primary_10_1097_MCC_0000000000001142 crossref_primary_10_1016_j_parkreldis_2023_105515 crossref_primary_10_1007_s00415_024_12863_7 crossref_primary_10_1007_s10072_025_08027_8 crossref_primary_10_1038_s41598_024_62460_x crossref_primary_10_3390_ijms25063554 crossref_primary_10_1016_j_jns_2024_122932 crossref_primary_10_1016_j_parkreldis_2024_107047 crossref_primary_10_1111_jnp_70010 crossref_primary_10_1002_mdc3_70327 crossref_primary_10_1007_s00702_025_03006_x crossref_primary_10_1016_j_parkreldis_2025_107343 crossref_primary_10_1002_mdc3_14200 crossref_primary_10_1002_mds_30071 crossref_primary_10_1002_mds_30191 crossref_primary_10_1007_s00415_024_12632_6 crossref_primary_10_1016_j_prdoa_2025_100373 crossref_primary_10_1177_1877718X251315375 crossref_primary_10_3390_bs14020101 crossref_primary_10_2196_63153 crossref_primary_10_1111_pcn_13814 crossref_primary_10_1111_ene_16535 crossref_primary_10_3389_fneur_2025_1628697 crossref_primary_10_1016_j_ebiom_2025_105917 crossref_primary_10_2147_NDT_S474584 crossref_primary_10_1016_j_prdoa_2025_100378 crossref_primary_10_3390_brainsci14121244 crossref_primary_10_1016_j_parkreldis_2025_107905 crossref_primary_10_1177_26331055251329878 crossref_primary_10_3390_jcm14165749 crossref_primary_10_1002_mdc3_70290 crossref_primary_10_1038_s41531_025_00930_3 crossref_primary_10_1111_pcn_13817 crossref_primary_10_3390_jpm14101023 crossref_primary_10_1038_s41531_024_00695_1 crossref_primary_10_3389_fbioe_2024_1428189 crossref_primary_10_1371_journal_pone_0317389 crossref_primary_10_1159_000542791 crossref_primary_10_1002_brb3_70069 crossref_primary_10_3389_fneur_2024_1459576 crossref_primary_10_1016_j_parkreldis_2025_107954 crossref_primary_10_3390_biom14081022 crossref_primary_10_1002_acn3_70183 crossref_primary_10_1007_s00415_023_12162_7 crossref_primary_10_1177_1877718X241288712 crossref_primary_10_1016_j_brs_2025_08_002 crossref_primary_10_1155_2024_5550362 crossref_primary_10_1002_mdc3_70231 crossref_primary_10_3989_mc_2023_297522 crossref_primary_10_1111_ene_16420 crossref_primary_10_3390_s23218971 crossref_primary_10_1007_s00415_024_12783_6 crossref_primary_10_1007_s00259_024_06796_6 crossref_primary_10_1155_2024_6052552 crossref_primary_10_1038_s41467_025_60695_4 crossref_primary_10_1016_j_bioorg_2024_107488 crossref_primary_10_1002_ana_27223 crossref_primary_10_1186_s42466_025_00409_9 crossref_primary_10_3389_fnins_2025_1577588 crossref_primary_10_1007_s10072_023_06999_z crossref_primary_10_3389_fneur_2025_1591664 crossref_primary_10_1371_journal_pmed_1004670 crossref_primary_10_1016_j_parkreldis_2025_107321 crossref_primary_10_1186_s12964_025_02153_8 crossref_primary_10_7759_cureus_65316 crossref_primary_10_1002_iub_2822 crossref_primary_10_1016_j_nbd_2024_106659 crossref_primary_10_1212_WNL_0000000000210192 crossref_primary_10_1016_j_jns_2024_123366 crossref_primary_10_1016_j_nbd_2024_106413 crossref_primary_10_3389_fneur_2023_1213772 crossref_primary_10_1007_s44411_025_00142_4 crossref_primary_10_1007_s40520_024_02922_4 crossref_primary_10_1111_cns_70424 crossref_primary_10_3389_fneur_2023_1279161 crossref_primary_10_1038_s41531_025_01092_y crossref_primary_10_1002_mds_29959 crossref_primary_10_1038_s41531_025_01106_9 crossref_primary_10_1136_jnnp_2023_332272 crossref_primary_10_1002_mds_29678 crossref_primary_10_1038_s41531_024_00745_8 crossref_primary_10_1272_jnms_JNMS_2025_92_304 crossref_primary_10_1002_mds_29830 crossref_primary_10_1177_08919887241313376 crossref_primary_10_3233_JPD_240026 crossref_primary_10_1016_j_parkreldis_2024_107134 crossref_primary_10_1038_s41531_025_01031_x crossref_primary_10_2196_64213 crossref_primary_10_1002_mdc3_14352 crossref_primary_10_1002_mds_30146 crossref_primary_10_1002_mdc3_70254 crossref_primary_10_1002_mdc3_70094 crossref_primary_10_1212_CPJ_0000000000200506 crossref_primary_10_1016_j_sleep_2025_03_007 crossref_primary_10_1007_s40120_025_00800_3 crossref_primary_10_1016_j_jns_2024_122958 crossref_primary_10_1002_ana_27005 crossref_primary_10_1002_mdc3_70128 crossref_primary_10_1002_mdc3_70249 crossref_primary_10_1016_j_parkreldis_2025_107300 crossref_primary_10_1038_s41531_025_00937_w crossref_primary_10_1177_1877718X241305626 crossref_primary_10_1177_17562864241277157 crossref_primary_10_1002_acn3_51975 crossref_primary_10_1016_j_neuroimage_2025_121354 crossref_primary_10_1002_mdc3_70247 crossref_primary_10_1177_1877718X251344896 crossref_primary_10_1097_MNM_0000000000001946 crossref_primary_10_1002_mdc3_70240 crossref_primary_10_1002_mds_30159 crossref_primary_10_1016_j_jns_2024_123266 crossref_primary_10_1007_s00415_025_13390_9 crossref_primary_10_3389_fneur_2025_1477827 crossref_primary_10_1002_mdc3_14358 crossref_primary_10_1016_j_clinph_2025_2110958 crossref_primary_10_1007_s00415_024_12752_z crossref_primary_10_1007_s10072_023_07238_1 crossref_primary_10_1016_j_clineuro_2025_108919 crossref_primary_10_18311_jnr_2025_47860 |
| Cites_doi | 10.1002/mdc3.12595 10.1111/ene.15651 10.1080/01616412.2021.1942408 10.1007/s40120-019-0144-1 10.1111/bcp.13651 10.1002/pds.2114 10.1186/s12883-022-02600-w 10.1016/j.amjopharm.2010.07.002 10.1007/s004150200059 10.2217/nmt-2017-0020 10.1111/rssa.12579 10.1056/NEJM200006083422304 10.1007/s00228-014-1701-2 10.1038/srep45865 10.3233/JPD-181427 10.1378/chest.129.1.174 10.1017/cjn.2017.208 10.3233/JPD-191769 10.1212/01.WNL.0000103235.12621.C3 10.1016/j.parkreldis.2020.05.020 10.1007/s00702-020-02257-0 10.1002/mdc3.12921 10.1002/mds.10186 10.3233/JAD-161068 10.1136/bmj.a744 10.1002/mdc3.12632 10.1016/S0140-6736(95)92404-3 10.1111/cts.13008 10.1007/s40262-018-0663-4 10.1002/mds.27386 10.1136/bmj.39489.470347.AD 10.1016/j.cmpb.2020.105633 10.5662/wjm.v12.i3.92 10.3390/brainsci10030176 10.1515/jci-2016-0014 10.1002/mds.27602 10.2165/11588230-000000000-00000 10.1016/j.ensci.2020.100257 10.1016/j.parkreldis.2022.03.012 10.1212/WNL.50.5_Suppl_5.S31 10.1001/jama.287.4.455 10.3390/brainsci9100272 10.1093/brain/awf084 10.3233/JPD-150622 10.1056/NEJMoa060281 10.1212/WNL.49.1.249 10.1212/01.wnl.0000250236.75053.16 10.2217/cer-2020-0042 10.1007/s40120-021-00251-6 10.1007/s10072-018-3272-y 10.1371/journal.pone.0138237 10.1007/s13167-011-0067-0 10.3389/fphar.2022.858139 10.1002/mds.27372 10.1212/WNL.56.9.1239 10.1007/s00228-017-2196-4 10.1002/mds.28669 10.1016/j.jcrc.2017.09.178 10.1016/j.envsoft.2019.104588 10.1093/brain/121.3.451 10.3390/jpm11040254 10.1212/WNL.0000000000012868 10.1126/scitranslmed.aad8858 10.1002/mds.26286 10.1007/s00228-020-02961-6 10.1111/ncn3.12026 10.2147/CIA.S151919 10.3389/fneur.2021.707723 10.1002/mds.23429 |
| ContentType | Journal Article |
| Copyright | 2023 The Authors. published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. 2023. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2023 The Authors. published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. – notice: 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. – notice: 2023. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| CorporateAuthor | the International Parkinson and Movement Disorders Society Non‐Motor Parkinson Disease Study Group International Parkinson and Movement Disorders Society Non-Motor Parkinson Disease Study Group Lunds universitets profilområden Institutionen för kliniska vetenskaper, Lund LU Profile Area: Proactive Ageing MultiPark: Multidisciplinary research focused on Parkinson's disease Lunds universitet Profile areas and other strong research environments Lund University Restorative Parkinson Unit Lund University Profile areas Department of Clinical Sciences, Lund Neurology, Lund Strategiska forskningsområden (SFO) Faculty of Medicine Strategic research areas (SRA) Section IV Medicinska fakulteten Sektion IV LU profilområde: Proaktivt åldrande Profilområden och andra starka forskningsmiljöer Neurologi, Lund |
| CorporateAuthor_xml | – name: the International Parkinson and Movement Disorders Society Non‐Motor Parkinson Disease Study Group – name: International Parkinson and Movement Disorders Society Non-Motor Parkinson Disease Study Group – name: Faculty of Medicine – name: Medicinska fakulteten – name: Strategiska forskningsområden (SFO) – name: Restorative Parkinson Unit – name: LU profilområde: Proaktivt åldrande – name: Institutionen för kliniska vetenskaper, Lund – name: Strategic research areas (SRA) – name: Neurology, Lund – name: Lunds universitet – name: Department of Clinical Sciences, Lund – name: Lunds universitets profilområden – name: Lund University Profile areas – name: Sektion IV – name: Profilområden och andra starka forskningsmiljöer – name: Lund University – name: Section IV – name: LU Profile Area: Proactive Ageing – name: Neurologi, Lund – name: Profile areas and other strong research environments – name: MultiPark: Multidisciplinary research focused on Parkinson's disease |
| DBID | 24P AAYXX CITATION NPM 7TK 8FD FR3 K9. NAPCQ P64 RC3 7X8 ADTPV AGCHP AOWAS D8T D95 ZZAVC |
| DOI | 10.1002/mds.29410 |
| DatabaseName | Wiley-Blackwell Open Access Collection CrossRef PubMed Neurosciences Abstracts Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic SwePub SWEPUB Lunds universitet full text SwePub Articles SWEPUB Freely available online SWEPUB Lunds universitet SwePub Articles full text |
| DatabaseTitle | CrossRef PubMed Nursing & Allied Health Premium Genetics Abstracts Technology Research Database ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | Nursing & Allied Health Premium MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1531-8257 |
| EndPage | 1252 |
| ExternalDocumentID | oai_portal_research_lu_se_publications_c5047c00_5e31_4fb5_aefc_713943c34cf3 37147135 10_1002_mds_29410 MDS29410 |
| Genre | article Journal Article |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 123 1CY 1L6 1OB 1OC 1ZS 24P 31~ 33P 3PY 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC FYBCS G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6M MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWD RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TWZ UB1 V2E V9Y W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WXI WXSBR XG1 XV2 YCJ ZGI ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION O8X NPM 7TK 8FD FR3 K9. NAPCQ P64 RC3 7X8 ADTPV AGCHP AOWAS D8T D95 ZZAVC |
| ID | FETCH-LOGICAL-c5440-74e698c851cbfe646977d0aa33f09076be4417946b861a428d24241dbaade1f3 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 190 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000992580000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0885-3185 1531-8257 |
| IngestDate | Tue Dec 02 03:10:39 EST 2025 Thu Oct 02 10:59:16 EDT 2025 Sat Nov 29 14:41:19 EST 2025 Thu Apr 03 07:09:51 EDT 2025 Sat Nov 29 07:08:23 EST 2025 Tue Nov 18 19:47:20 EST 2025 Wed Jan 22 16:18:22 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | levodopa equivalent daily dose LEDD levodopa equivalent dose |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5440-74e698c851cbfe646977d0aa33f09076be4417946b861a428d24241dbaade1f3 |
| Notes | registration number Stefanie T. Jost and Marie‐Ann Kaldenbach contributed equally. None. PROSPERO Financial Disclosure/Conflict of Interest concerning the research related to the manuscript CRD42021239664. K. Ray Chaudhuri and Haidar S. Dafsari contributed equally. Funding sources of the study Correction added on 19 May 2023, after first online publication: The affiliation of K. Ray Chaudhuri has changed in this version. ObjectType-Article-1 ObjectType-Evidence Based Healthcare-3 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| ORCID | 0000-0003-0477-2289 0000-0002-6901-2064 0000-0003-3085-2282 0000-0002-3389-136X 0000-0001-5346-0180 0000-0002-4610-947X 0000-0003-0808-0116 0000-0002-6041-9941 0000-0003-0837-5280 0000-0002-6316-6804 0000-0003-0633-7168 0000-0003-0749-3840 0000-0003-1040-2807 0000-0002-4176-9196 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmds.29410 |
| PMID | 37147135 |
| PQID | 2843042558 |
| PQPubID | 1016421 |
| PageCount | 17 |
| ParticipantIDs | swepub_primary_oai_portal_research_lu_se_publications_c5047c00_5e31_4fb5_aefc_713943c34cf3 proquest_miscellaneous_2810918047 proquest_journals_2843042558 pubmed_primary_37147135 crossref_citationtrail_10_1002_mds_29410 crossref_primary_10_1002_mds_29410 wiley_primary_10_1002_mds_29410_MDS29410 |
| PublicationCentury | 2000 |
| PublicationDate | July 2023 |
| PublicationDateYYYYMMDD | 2023-07-01 |
| PublicationDate_xml | – month: 07 year: 2023 text: July 2023 |
| PublicationDecade | 2020 |
| PublicationPlace | Hoboken, USA |
| PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: Hoboken |
| PublicationTitle | Movement disorders |
| PublicationTitleAlternate | Mov Disord |
| PublicationYear | 2023 |
| Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
| References | 2002; 17 2017; 7 2019; 2019 2017; 8 2023; 30 2014; 70 2004; 62 2020; 20 2017; 44 2015; 30 2019; 58 2020; 127 1997; 49 2018; 84 2020; 124 2020; 10 2022; 22 2018; 43 2021; 36 2017; 73 2020; 7 2018; 39 2010; 25 2018; 5 2014; 2 2020; 9 2011; 20 1998; 50 2018; 33 1998; 121 2001; 56 2006; 129 2007; 68 2010; 8 2019; 8 2019; 9 2021; 43 2015; 5 2015; 4 2011; 2 2003; 2002 2019; 34 2015; 10 2020; 183 2014; 2014 2011; 34 2020; 76 2006; 355 2021; 14 2016; 4 2021; 10 2021; 97 2021; 12 2021; 11 2022 2020; 196 2004; 19 2002; 125 2002; 287 2017; 12 2017; 56 2002; 249 2022; 12 2022; 13 2008; 337 1995; 346 2008; 336 2022; 97 2000; 342 2016; 8 e_1_2_9_75_1 e_1_2_9_31_1 e_1_2_9_52_1 e_1_2_9_50_1 e_1_2_9_73_1 e_1_2_9_35_1 e_1_2_9_56_1 e_1_2_9_77_1 e_1_2_9_12_1 e_1_2_9_33_1 Lefebvre C (e_1_2_9_10_1) 2022 e_1_2_9_71_1 e_1_2_9_14_1 e_1_2_9_39_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_58_1 e_1_2_9_18_1 e_1_2_9_41_1 e_1_2_9_64_1 e_1_2_9_20_1 e_1_2_9_62_1 e_1_2_9_22_1 e_1_2_9_45_1 e_1_2_9_68_1 e_1_2_9_24_1 e_1_2_9_43_1 e_1_2_9_66_1 e_1_2_9_8_1 e_1_2_9_6_1 e_1_2_9_4_1 e_1_2_9_60_1 e_1_2_9_2_1 e_1_2_9_26_1 e_1_2_9_28_1 e_1_2_9_47_1 Pitcher TL (e_1_2_9_55_1) 2014; 2014 Katzenschlager R (e_1_2_9_59_1) 2003; 2002 Murata M (e_1_2_9_49_1) 2004; 19 e_1_2_9_30_1 e_1_2_9_53_1 e_1_2_9_74_1 e_1_2_9_51_1 e_1_2_9_72_1 e_1_2_9_11_1 e_1_2_9_34_1 Orayj K (e_1_2_9_57_1) 2019; 2019 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_76_1 e_1_2_9_70_1 Junjaiah VK (e_1_2_9_54_1) 2014; 2 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_19_1 e_1_2_9_42_1 e_1_2_9_63_1 e_1_2_9_40_1 e_1_2_9_61_1 e_1_2_9_21_1 e_1_2_9_46_1 e_1_2_9_67_1 e_1_2_9_23_1 e_1_2_9_44_1 e_1_2_9_65_1 e_1_2_9_7_1 e_1_2_9_5_1 e_1_2_9_3_1 e_1_2_9_9_1 e_1_2_9_25_1 e_1_2_9_27_1 e_1_2_9_48_1 e_1_2_9_69_1 e_1_2_9_29_1 |
| References_xml | – volume: 25 start-page: 2649 issue: 15 year: 2010 end-page: 2653 article-title: Systematic review of levodopa dose equivalency reporting in Parkinson's disease publication-title: Mov Disord – volume: 33 start-page: 909 issue: 6 year: 2018 end-page: 919 article-title: Motor and nonmotor complications of levodopa: phenomenology, risk factors, and imaging features publication-title: Mov Disord – volume: 17 start-page: 682 issue: 4 year: 2002 end-page: 692 article-title: Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: a case series of 115 patients publication-title: Mov Disord – volume: 14 start-page: 1464 issue: 4 year: 2021 end-page: 1475 article-title: Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease publication-title: Clin Transl Sci – volume: 7 start-page: 343 issue: 3 year: 2020 end-page: 345 article-title: Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide publication-title: Mov Disord Clin Pract – volume: 56 start-page: 1239 issue: 9 year: 2001 end-page: 1242 article-title: Dual‐release formulation, a novel principle in L‐dopa treatment of Parkinson's disease publication-title: Neurology – volume: 8 start-page: 449 issue: 2 year: 2019 end-page: 460 article-title: Bioavailability and pharmacokinetics of once‐daily amantadine extended‐release tablets in healthy volunteers: results from three randomized, crossover, open‐label, phase 1 studies publication-title: Neurol Ther – volume: 76 start-page: 1731 issue: 12 year: 2020 end-page: 1743 article-title: Comparative effectiveness of dopamine agonists and monoamine oxidase type‐B inhibitors for Parkinson's disease: a multiple treatment comparison meta‐analysis publication-title: Eur J Clin Pharmacol – volume: 70 start-page: 1059 issue: 9 year: 2014 end-page: 1071 article-title: Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations publication-title: Eur J Clin Pharmacol – volume: 36 start-page: 2393 issue: 10 year: 2021 end-page: 2407 article-title: Availability of therapies and services for Parkinson's disease in Africa: a continent‐wide survey publication-title: Mov Disord – volume: 20 year: 2020 article-title: Prescription pattern of anti‐Parkinson's disease drugs in Japan based on a nationwide medical claims database publication-title: eNeurologicalSci – volume: 125 start-page: 871 issue: Pt 4 year: 2002 end-page: 879 article-title: Force overflow and levodopa‐induced dyskinesias in Parkinson's disease publication-title: Brain – volume: 30 start-page: 1118 issue: 4 year: 2023 end-page: 1134 article-title: Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta‐analysis of randomized controlled trials publication-title: Eur J Neurol – volume: 8 issue: 360 year: 2016 article-title: Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease publication-title: Sci Transl Med – volume: 12 start-page: 2095 year: 2017 end-page: 2108 article-title: Average annual cost of Parkinson's disease in Sao Paulo, Brazil, with a focus on disease‐related motor symptoms publication-title: Clin Interv Aging – volume: 76 start-page: 16 year: 2020 end-page: 20 article-title: Female, aging, difference formulations of DCI, or lower body weight increases AUC4hr of levodopa in patients with Parkinson's disease publication-title: Parkinsonism Relat Disord – volume: 22 start-page: 71 issue: 1 year: 2022 article-title: Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa‐containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study publication-title: BMC Neurol – volume: 336 start-page: 924 issue: 7650 year: 2008 end-page: 926 article-title: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations publication-title: BMJ – volume: 337 year: 2008 article-title: Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive publication-title: BMJ – volume: 11 start-page: 254 issue: 4 year: 2021 article-title: Initial experience of the levodopa‐entacapone‐carbidopa intestinal gel in clinical practice publication-title: J Pers Med – volume: 10 start-page: 173 issue: 1 year: 2020 end-page: 178 article-title: A real‐life search for the optimal set of conversion factors to levodopa‐equivalent‐dose in Parkinson's disease patients on polytherapy publication-title: J Parkinson's Dis – volume: 19 issue: Suppl 9 year: 2004 article-title: Randomized, double‐blind study of zonisamide with placebo in advanced Parkinson's disease publication-title: Mov Disord – volume: 124 year: 2020 article-title: Certain trends in uncertainty and sensitivity analysis: an overview of software tools and techniques publication-title: Environ Modell Softw – volume: 355 start-page: 896 issue: 9 year: 2006 end-page: 908 article-title: A randomized trial of deep‐brain stimulation for Parkinson's disease publication-title: N Engl J Med – year: 2022 – volume: 39 start-page: 733 issue: 4 year: 2018 end-page: 739 article-title: Real life evaluation of safinamide effectiveness in Parkinson's disease publication-title: Neurol Sci – volume: 50 start-page: S31 issue: 5 year: 1998 end-page: S38 article-title: Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers publication-title: Neurology – volume: 10 start-page: 176 issue: 3 year: 2020 article-title: A Spanish consensus on the use of safinamide for Parkinson's disease in clinical practice publication-title: Brain Sci – volume: 2 start-page: 49 issue: 1 year: 2011 end-page: 57 article-title: A Japanese health success story: trends in cardiovascular diseases, their risk factors, and the contribution of public health and personalized approaches publication-title: EPMA J – volume: 49 start-page: 249 issue: 1 year: 1997 end-page: 253 article-title: High‐frequency stimulation of the globus pallidus for the treatment of Parkinson's disease publication-title: Neurology – volume: 2014 year: 2014 article-title: Trends in antiparkinsonian medication use in New Zealand: 1995‐2011 publication-title: Parkinson's Dis – volume: 97 start-page: 942 issue: 20 year: 2021 end-page: 957 article-title: Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN guideline subcommittee publication-title: Neurology – volume: 249 start-page: 529 issue: 5 year: 2002 end-page: 534 article-title: Subthalamic nucleus stimulation in Parkinson's disease: clinical evaluation of 18 patients publication-title: J Neurol – volume: 34 start-page: 329 issue: 4 year: 2011 end-page: 338 article-title: The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008 publication-title: Drug Saf – volume: 5 start-page: 837 issue: 4 year: 2015 end-page: 845 article-title: Conversion to IPX066 from standard levodopa formulations in advanced Parkinson's disease: experience in clinical trials publication-title: J Parkinson's Dis – volume: 43 start-page: 327 year: 2018 end-page: 339 article-title: Major publications in the critical care pharmacotherapy literature: January‐December 2016 publication-title: J Crit Care – volume: 10 start-page: 693 issue: 2 year: 2021 end-page: 709 article-title: Pharmacokinetics and comparative bioavailability of apomorphine sublingual film and subcutaneous apomorphine formulations in patients with Parkinson's disease and "OFF" episodes: results of a randomized, three‐way crossover, open‐label study publication-title: Neurol Ther – volume: 287 start-page: 455 issue: 4 year: 2002 end-page: 463 article-title: Excessive daytime sleepiness and sudden‐onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group publication-title: JAMA – volume: 9 start-page: 737 issue: 10 year: 2020 end-page: 750 article-title: Causal inference and adjustment for reference‐arm risk in indirect treatment comparison meta‐analysis publication-title: J Comp Eff Res – volume: 97 start-page: 68 year: 2022 end-page: 72 article-title: Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa‐carbidopa intestinal gel delivered to the jejunum publication-title: Parkinsonism Relat Disord – volume: 2002 issue: 2 year: 2003 article-title: Anticholinergics for symptomatic management of Parkinson's disease publication-title: Cochrane Database Syst Rev – volume: 43 start-page: 950 issue: 11 year: 2021 end-page: 954 article-title: Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study publication-title: Neurol Res – volume: 12 year: 2021 article-title: Different catechol‐O‐methyl transferase inhibitors in Parkinson's disease: a Bayesian network meta‐analysis publication-title: Front Neurol – volume: 13 year: 2022 article-title: Real‐world prescription patterns for patients with young‐onset Parkinson's disease in China: a trend analysis from 2014 to 2019 publication-title: Front Pharmacol – volume: 8 start-page: 384 issue: 4 year: 2010 end-page: 394 article-title: Use of antiparkinson medications among elderly Medicare beneficiaries with Parkinson's disease publication-title: Am J Geriatr Pharmacother – volume: 7 start-page: 299 issue: 5 year: 2017 end-page: 306 article-title: Prescription pattern and awareness of disease and treatment in patients of Parkinson's disease publication-title: Neurodegener Dis Manage – volume: 62 start-page: 201 issue: 2 year: 2004 end-page: 207 article-title: Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial publication-title: Neurology – volume: 68 start-page: 45 issue: 1 year: 2007 end-page: 50 article-title: Zonisamide improves motor function in Parkinson disease: a randomized, double‐blind study publication-title: Neurology – volume: 10 issue: 9 year: 2015 article-title: The role of Google Scholar in evidence reviews and its applicability to grey literature searching publication-title: PLoS One – volume: 129 start-page: 174 issue: 1 year: 2006 end-page: 181 article-title: Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force publication-title: Chest – volume: 4 issue: 2 year: 2016 article-title: A causal inference approach to network meta‐analysis publication-title: J Causal Inference – volume: 58 start-page: 77 issue: 1 year: 2019 end-page: 88 article-title: Pharmacokinetics of ADS‐5102 (amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia publication-title: Clin Pharmacokinet – volume: 5 start-page: 183 issue: 2 year: 2018 end-page: 190 article-title: Parkinson's patients with dyskinesia switched from immediate release amantadine to open‐label ADS‐5102 publication-title: Mov Disord Clin Pract – volume: 9 start-page: 272 issue: 10 year: 2019 article-title: Safinamide in clinical practice: a Spanish multicenter cohort study publication-title: Brain Sci – volume: 44 start-page: 705 issue: 6 year: 2017 end-page: 710 article-title: Prescribing pattern for Parkinson's disease in Indian community before referral to tertiary center publication-title: Can J Neurol Sci – volume: 8 year: 2017 article-title: Comparison for efficacy and tolerability among ten drugs for treatment of Parkinson's disease: a network meta‐analysis publication-title: Sci Rep – volume: 84 start-page: 1917 issue: 9 year: 2018 end-page: 1927 article-title: A multiple treatment comparison meta‐analysis of monoamine oxidase type B inhibitors for Parkinson's disease publication-title: Br J Clin Pharmacol – volume: 34 start-page: 180 issue: 2 year: 2019 end-page: 198 article-title: Update on treatments for nonmotor symptoms of Parkinson's disease‐an evidence‐based medicine review publication-title: Mov Disord – volume: 20 start-page: 450 issue: 5 year: 2011 end-page: 456 article-title: Utilization of anti‐Parkinson drugs in Australia: 1995‐2009 publication-title: Pharmacoepidemiol Drug Saf – volume: 56 start-page: 1229 issue: 4 year: 2017 end-page: 1239 article-title: Combination therapy with zonisamide and antiparkinson drugs for Parkinson's disease: a meta‐analysis publication-title: J Alzheimer's Dis – volume: 127 start-page: 1599 issue: 12 year: 2020 end-page: 1606 article-title: Comparison of effectiveness of trihexyphenidyl and levodopa on motor symptoms in Parkinson's disease publication-title: J Neural Transm – volume: 12 start-page: 92 issue: 3 year: 2022 end-page: 98 article-title: Network meta‐analyses: methodological prerequisites and clinical usefulness publication-title: World J Methodol – volume: 121 start-page: 451 issue: Pt 3 year: 1998 end-page: 457 article-title: Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease publication-title: Brain – volume: 346 start-page: 1383 issue: 8987 year: 1995 end-page: 1387 article-title: Effect of GPi pallidotomy on motor function in Parkinson's disease publication-title: Lancet – volume: 4 start-page: 10 issue: 1 year: 2015 end-page: 15 article-title: Randomized placebo‐controlled trial of zonisamide in patients with Parkinson's disease publication-title: Neurol Clin Neurosci – volume: 2019 year: 2019 article-title: Patterns and determinants of prescribing for Parkinson's disease: a systematic literature review publication-title: Parkinson's Dis – volume: 196 year: 2020 article-title: EQUIDopa: a responsive web application for the levodopa equivalent dose calculator publication-title: Comput Methods Programs Biomed – volume: 5 start-page: 448 issue: 4 year: 2018 end-page: 450 article-title: Minimal clinically important difference for UPDRS‐III in daily practice publication-title: Mov Disord Clin Pract – volume: 73 start-page: 563 issue: 5 year: 2017 end-page: 571 article-title: Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment publication-title: Eur J Clin Pharmacol – volume: 342 start-page: 1708 issue: 23 year: 2000 end-page: 1714 article-title: Long‐term follow‐up of unilateral pallidotomy in advanced Parkinson's disease publication-title: N Engl J Med – volume: 9 start-page: 153 issue: 1 year: 2019 end-page: 156 article-title: Conversion of L‐dopa to extended release L‐dopa (Rytary®) in patients with fluctuating Parkinson's disease: predictors of dose publication-title: J Parkinson's Dis – volume: 33 start-page: 1248 issue: 8 year: 2018 end-page: 1266 article-title: International Parkinson and Movement Disorder Society evidence‐based medicine review: update on treatments for the motor symptoms of Parkinson's disease publication-title: Mov Disord – volume: 2 start-page: 420 year: 2014 end-page: 429 article-title: A prospective study of the drug prescribing rate and pattern and assessment of adverse drug reactions in patients with idiopathic Parkinson disease in a tertiary care hospital publication-title: Am J Phytomed Clin Ther – volume: 30 start-page: 1343 issue: 10 year: 2015 end-page: 1350 article-title: Zonisamide improves wearing‐off in Parkinson's disease: a randomized, double‐blind study publication-title: Mov Disord – volume: 183 start-page: 1189 issue: 3 year: 2020 end-page: 1210 article-title: Multilevel network meta‐regression for population‐adjusted treatment comparisons publication-title: J R Stat Soc, Ser A – ident: e_1_2_9_39_1 doi: 10.1002/mdc3.12595 – ident: e_1_2_9_76_1 doi: 10.1111/ene.15651 – ident: e_1_2_9_43_1 doi: 10.1080/01616412.2021.1942408 – ident: e_1_2_9_38_1 doi: 10.1007/s40120-019-0144-1 – ident: e_1_2_9_45_1 doi: 10.1111/bcp.13651 – ident: e_1_2_9_58_1 doi: 10.1002/pds.2114 – ident: e_1_2_9_62_1 doi: 10.1186/s12883-022-02600-w – ident: e_1_2_9_9_1 doi: 10.1016/j.amjopharm.2010.07.002 – ident: e_1_2_9_20_1 doi: 10.1007/s004150200059 – ident: e_1_2_9_6_1 doi: 10.2217/nmt-2017-0020 – ident: e_1_2_9_72_1 doi: 10.1111/rssa.12579 – ident: e_1_2_9_17_1 doi: 10.1056/NEJM200006083422304 – ident: e_1_2_9_34_1 doi: 10.1007/s00228-014-1701-2 – ident: e_1_2_9_75_1 doi: 10.1038/srep45865 – volume-title: Cochrane handbook for systematic reviews of interventions version 6.3 year: 2022 ident: e_1_2_9_10_1 – ident: e_1_2_9_26_1 doi: 10.3233/JPD-181427 – ident: e_1_2_9_64_1 doi: 10.1378/chest.129.1.174 – ident: e_1_2_9_53_1 doi: 10.1017/cjn.2017.208 – ident: e_1_2_9_68_1 doi: 10.3233/JPD-191769 – ident: e_1_2_9_22_1 doi: 10.1212/01.WNL.0000103235.12621.C3 – ident: e_1_2_9_69_1 doi: 10.1016/j.parkreldis.2020.05.020 – ident: e_1_2_9_60_1 doi: 10.1007/s00702-020-02257-0 – ident: e_1_2_9_32_1 doi: 10.1002/mdc3.12921 – volume: 19 issue: 9 year: 2004 ident: e_1_2_9_49_1 article-title: Randomized, double‐blind study of zonisamide with placebo in advanced Parkinson's disease publication-title: Mov Disord – ident: e_1_2_9_19_1 doi: 10.1002/mds.10186 – ident: e_1_2_9_51_1 doi: 10.3233/JAD-161068 – ident: e_1_2_9_13_1 doi: 10.1136/bmj.a744 – ident: e_1_2_9_61_1 doi: 10.1002/mdc3.12632 – ident: e_1_2_9_15_1 doi: 10.1016/S0140-6736(95)92404-3 – ident: e_1_2_9_37_1 doi: 10.1111/cts.13008 – ident: e_1_2_9_40_1 doi: 10.1007/s40262-018-0663-4 – ident: e_1_2_9_2_1 doi: 10.1002/mds.27386 – ident: e_1_2_9_63_1 doi: 10.1136/bmj.39489.470347.AD – ident: e_1_2_9_31_1 doi: 10.1016/j.cmpb.2020.105633 – ident: e_1_2_9_71_1 doi: 10.5662/wjm.v12.i3.92 – ident: e_1_2_9_41_1 doi: 10.3390/brainsci10030176 – volume: 2 start-page: 420 year: 2014 ident: e_1_2_9_54_1 article-title: A prospective study of the drug prescribing rate and pattern and assessment of adverse drug reactions in patients with idiopathic Parkinson disease in a tertiary care hospital publication-title: Am J Phytomed Clin Ther – ident: e_1_2_9_74_1 doi: 10.1515/jci-2016-0014 – ident: e_1_2_9_66_1 doi: 10.1002/mds.27602 – ident: e_1_2_9_56_1 doi: 10.2165/11588230-000000000-00000 – ident: e_1_2_9_7_1 doi: 10.1016/j.ensci.2020.100257 – ident: e_1_2_9_30_1 doi: 10.1016/j.parkreldis.2022.03.012 – ident: e_1_2_9_35_1 doi: 10.1212/WNL.50.5_Suppl_5.S31 – ident: e_1_2_9_14_1 doi: 10.1001/jama.287.4.455 – ident: e_1_2_9_44_1 doi: 10.3390/brainsci9100272 – ident: e_1_2_9_18_1 doi: 10.1093/brain/awf084 – ident: e_1_2_9_25_1 doi: 10.3233/JPD-150622 – ident: e_1_2_9_23_1 doi: 10.1056/NEJMoa060281 – ident: e_1_2_9_21_1 doi: 10.1212/WNL.49.1.249 – ident: e_1_2_9_47_1 doi: 10.1212/01.wnl.0000250236.75053.16 – volume: 2002 issue: 2 year: 2003 ident: e_1_2_9_59_1 article-title: Anticholinergics for symptomatic management of Parkinson's disease publication-title: Cochrane Database Syst Rev – ident: e_1_2_9_73_1 doi: 10.2217/cer-2020-0042 – volume: 2019 year: 2019 ident: e_1_2_9_57_1 article-title: Patterns and determinants of prescribing for Parkinson's disease: a systematic literature review publication-title: Parkinson's Dis – ident: e_1_2_9_36_1 doi: 10.1007/s40120-021-00251-6 – ident: e_1_2_9_42_1 doi: 10.1007/s10072-018-3272-y – volume: 2014 year: 2014 ident: e_1_2_9_55_1 article-title: Trends in antiparkinsonian medication use in New Zealand: 1995‐2011 publication-title: Parkinson's Dis – ident: e_1_2_9_11_1 doi: 10.1371/journal.pone.0138237 – ident: e_1_2_9_52_1 doi: 10.1007/s13167-011-0067-0 – ident: e_1_2_9_8_1 doi: 10.3389/fphar.2022.858139 – ident: e_1_2_9_67_1 doi: 10.1002/mds.27372 – ident: e_1_2_9_24_1 doi: 10.1212/WNL.56.9.1239 – ident: e_1_2_9_28_1 doi: 10.1007/s00228-017-2196-4 – ident: e_1_2_9_4_1 doi: 10.1002/mds.28669 – ident: e_1_2_9_65_1 doi: 10.1016/j.jcrc.2017.09.178 – ident: e_1_2_9_70_1 doi: 10.1016/j.envsoft.2019.104588 – ident: e_1_2_9_12_1 – ident: e_1_2_9_16_1 doi: 10.1093/brain/121.3.451 – ident: e_1_2_9_29_1 doi: 10.3390/jpm11040254 – ident: e_1_2_9_77_1 doi: 10.1212/WNL.0000000000012868 – ident: e_1_2_9_27_1 doi: 10.1126/scitranslmed.aad8858 – ident: e_1_2_9_48_1 doi: 10.1002/mds.26286 – ident: e_1_2_9_46_1 doi: 10.1007/s00228-020-02961-6 – ident: e_1_2_9_50_1 doi: 10.1111/ncn3.12026 – ident: e_1_2_9_5_1 doi: 10.2147/CIA.S151919 – ident: e_1_2_9_33_1 doi: 10.3389/fneur.2021.707723 – ident: e_1_2_9_3_1 doi: 10.1002/mds.23429 |
| SSID | ssj0011516 |
| Score | 2.702273 |
| Snippet | Background
To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed.... To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are... BackgroundTo compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed.... Background: To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed.... |
| SourceID | swepub proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1236 |
| SubjectTerms | Basic Medicine Clinical trials Drug dosages Drug therapy Farmaceutiska vetenskaper LEDD Levodopa levodopa equivalent daily dose levodopa equivalent dose Medical and Health Sciences Medicin och hälsovetenskap Medicinska och farmaceutiska grundvetenskaper Movement disorders Neurodegenerative diseases Non-pharmacological intervention Parkinson's disease Pharmaceutical Sciences Reviews Systematic review |
| Title | Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmds.29410 https://www.ncbi.nlm.nih.gov/pubmed/37147135 https://www.proquest.com/docview/2843042558 https://www.proquest.com/docview/2810918047 |
| Volume | 38 |
| WOSCitedRecordID | wos000992580000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1531-8257 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011516 issn: 1531-8257 databaseCode: DRFUL dateStart: 19990101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5VLUJceFNSSmUQElxC49iOvXBCbFcc2mpFW2nhYvkpVirZbdPt78ePbKACJCQuUSRPnGQ8E88j8w3AK81qq1QtSk2wLqlzuNTcNKVnnmFiOdfGp2YT_PhYzGaj6Qa8X9fCZHyIIeAWNSN9r6OCK93t_wQN_W67t_WIxvKqLYyJiH0bajodUghhK2uyCclSifAaVqiq94dLb25Gv1mYA3zoTcs1bT2Te__10Pfhbm9xog9ZRB7Ahmsfwu2jPqf-CL4cuuvgmy4VGi86hw4uVvMgfbEiE81bFKuiU4HY6w6NczLnHTpbxjiBRScDDDTKOQakWoumsfFCF8T6MZxODk4_fir7hgulYTHHy6lrRsIEI8xo75rgOXNuK6UI8VVwohvtUsMy2mjRYBUcFxuLS7DVSlmHPXkCm-2idU8BVboS1NaeMMtomEppUnNjY8GQCkaQLeDNmvHS9GDksSfGucwwyrUMnJKJUwW8HEiXGYHjT0S769WTvRKGEUFjsIYxUcCLYTioT8yJqNYtVpEmIqOKivICtvOqD3eJYIaxg2EBX7MYDCMRkzu7R7LHZPomz1eyc3L5S7BVGhbmNVUlmSNYUq-ZVM4bGSYdUWIINZ4ETiSB-fu7yaPxSTrZ-XfSZ3CnDtZY_q94FzavLlfuOdwy11fz7nIvKUo48pnYg63x58nZ4Q9LgRh9 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaqFkEvvB-BAgYhwSU0ie0ki7ggtqsidlcV3UotF8tPdaWSXZpufz8zdjZQARISt0h2nGQyE88j3zeEvNKisEoVdapZrlPuXJ7qypSpF17kzFaVNj40m6im0_r4eHCwQd6vsTCRH6JPuKFlhO81GjgmpHd_soZ-s-3bYsARX7XFQY1Av7eGX0ZH476KALtZGb1IEVDCa2ahrNjtT766H_3mZPYMoled17D7jG79333fJjc7r5N-iGpyh2y45i65Punq6vfIydhdQny6VHS4aB3d-76agwYiKpPOG4rI6AASe93SYSzovKNHS8wVWHrYU0HTWGegqrH0AJsvtKDa98lstDf7uJ92TRdSI7DOW3FXDmoDjpjR3pUQPVeVzZRizGcQSJfahaZlvNR1mSsIXiwCTHKrlbIu9-wB2WwWjXtEaKazmtvCM2EFh6WUZkVlLIKGFDhCNiFv1pKXpiMkx74YZzJSKRcSJCWDpBLysp-6jCwcf5q0s359sjNEGKk5JmyEqBPyoh8GE8K6iGrcYoVzkB21zniVkIfxtfdXQUJD7GKYkK9RD_oR5OWOIZLseJlO5dlKtk4uf0m4SiNgXZNlUjiWS-61kMp5I2HRAWeGceMZSCJozN-fTU6Gh-Hg8b9PfU5u7M8mYzn-NP38hGwX4J3F_4x3yObF-co9JdfM5cW8PX_W2c0Pt2Ubew |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9RAEB_KVYov1m9TW11F0JfYJLub5KQvYnooXo_DtlB9WfYTD2ouNr3-_e5kc9GiguBbYDebZDKTnY_8fgPwQvHMSJmVsaKpipm1aawKnceOO55SUxRKu67ZRDGblWdn4_kGHKyxMIEfYki4oWV032s0cNsYt_-TNfSbaV9nY4b4qk2GTWRGsFl9mpxOhyqC383y4EXyDiW8ZhZKsv3h5Ov70W9O5sAget157Xafyfb_3fdtuNV7neRtUJM7sGHru7B11NfV78Hnqb3y8WkjSbVsLTn8vlp4DURUJlnUBJHRHUjsZUuqUNB5Q04bzBUYcjxQQZNQZyCyNmSOzRdar9r34WRyePLufdw3XYg1xzpvwWw-LrV3xLRyNvfRc1GYREpKXeID6VzZrmkZy1WZp9IHLwYBJqlRUhqbOvoARvWyto-AJCopmckc5YYzv5RUNCu0QdCQ9I6QieDVWvJC94Tk2BfjXAQq5Ux4SYlOUhE8H6Y2gYXjT5N2169P9IboR0qGCRvOywieDcPehLAuImu7XOEcZEctE1ZE8DC89uEqSGiIXQwj-BL0YBhBXu4QIomel-mrOF-J1orml4Sr0Nyvq5NEcEtTwZziQlqnhV90zKimTDvqJdFpzN-fTRxVx93Bzr9PfQpb82oiph9mHx_Dzcw7Z-E3410YXV6s7B7c0FeXi_biSW82PwAbNRr2 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Levodopa+Dose+Equivalency+in+Parkinson%27s+Disease&rft.jtitle=Movement+disorders&rft.au=Jost%2C+Stefanie+T.&rft.au=Kaldenbach%2C+Marie+Ann&rft.au=Antonini%2C+Angelo&rft.au=Martinez-Martin%2C+Pablo&rft.date=2023-07-01&rft.issn=1531-8257&rft.volume=38&rft.issue=7&rft.spage=1236&rft_id=info:doi/10.1002%2Fmds.29410&rft.externalDocID=oai_portal_research_lu_se_publications_c5047c00_5e31_4fb5_aefc_713943c34cf3 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0885-3185&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0885-3185&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0885-3185&client=summon |